Skip to main content

Table 1 A summary of conventional systemic immunosuppressive agents used to treat non-infectious uveitis

From: An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review



Typical dosage

Adverse effects

Price of typical one-year course of treatment for Behçet’s uveitis (£GBP)a

T-cell inhibitors


T-cell function inhibitor

2.5–10 mg/kg/day PO in 2 divided doses

Infections, nephrotoxicity, hypertension, hirsutism and gingival hyperplasia



T-cell function inhibitor

0.15–0.30 mg/kg/day PO

Infections, nephrotoxicity, hypertension, diabetes mellitus and electrolyte imbalance




Dihydrofolate reductase inhibitor

7.5–25 mg/week PO, SC, or IM

Infections, hepatotoxicity, oral ulcers, fatigue, alopecia, bone marrow suppression, pneumonitis, fetal loss and gastrointestinal disturbance



Purine metabolism inhibitor

1–4 mg/kg/day PO

Infections, hepatotoxicity, fatigue, bone marrow suppression, hypersensitivity and gastrointestinal disturbance


 Mycophenolate mofetil

Inosine monophosphate dehydrogenase inhibitor

500–1500 mg PO twice daily

Infections, bone marrow suppression, and gastrointestinal disturbance



Dihydroorotate dehydrogenase inhibitor

100 mg PO daily [×3 days], then 20 mg PO daily or every other day

Infections, bone marrow suppression, diarrhoea, hypertension and fetal loss


Alkylating agents


Alkylates nucleic acid

0.1–0.2 mg/kg/day PO

Infections, bone marrow suppression, increased risk of malignancy, and sterility



Alkylates nucleic acid

1–3 mg/kg/day PO

Infections, bone marrow suppression, hemorrhagic cystitis, increased risk of malignancy, sterility, and alopecia




Inhibits neutrophil motility

0.5–2 mg/day PO

Infections, peripheral neuropathy, bone marrow suppression, sterility and alopecia


  1. a Prices calculated according to recommended maintenance dose for one year of therapy for a 70 kg patient as prescribed and tested in up to date literature. Price as per BNF 70 [Joint formulary committee. British National Formulary. BNF 70 ed. London: BMJ Group and Pharmaceutical Press; September 2015]